flutamide has been researched along with Leanness in 1 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berruti, A | 1 |
| Dogliotti, L | 1 |
| Terrone, C | 1 |
| Cerutti, S | 1 |
| Isaia, G | 1 |
| Tarabuzzi, R | 1 |
| Reimondo, G | 1 |
| Mari, M | 1 |
| Ardissone, P | 1 |
| De Luca, S | 1 |
| Fasolis, G | 1 |
| Fontana, D | 1 |
| Rossetti, SR | 1 |
| Angeli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for flutamide and Leanness
| Article | Year |
|---|---|
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplasti | 2002 |